Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry

Current Drug Delivery

Volumn 10, Issue 1, 2013, Pages 46-53

  Hiemke, Christoph ^a   Shams, Mohamed ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Genotyping; Optimization of psychopharmacotherapy; Plasma concentration; Probe drug phenotyping; Therapeutic drug monitoring; Therapeutic reference range

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; BROMPERIDOL; CHLORPROTHIXENE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DESVENLAFAXINE; DOXEPIN; DRUG METABOLIZING ENZYME; ESCITALOPRAM; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE; HALOPERIDOL; ILOPERIDONE; IMIPRAMINE; NEUROLEPTIC AGENT; NORCLOMIPRAMINE; NORDOXEPIN; NORFLUOXETINE; NORTRIPTYLINE; UNINDEXED DRUG;

ARTICLE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; GENOTYPE; HUMAN; LONG TERM CARE; PHENOTYPE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RECURRENT DISEASE; RELAPSE;

DRUG MONITORING; GENOTYPE; HUMANS; PHENOTYPE; PSYCHOTROPIC DRUGS;

EID: 84875282049     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201811310010008     Document Type: Article

References (30)

1. Hirschfeld, R.M.A.; Montgomery, S.A.; Aguglia, E.; Amore, M.; Delgado, P.M.; Gastpar, M.; Hawley, C.; Kasper, S.; Linden, M.; Massana, J.; Mendlewicz, J.; Möller, H.J.; Nemeroff, C.B.; Saiz, J.; Such, P.; Torta, R.; Virsiani, M. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J. Clin. Psychiatry, 2002, 63, 826-837.
2. Bertilsson, L.; Mellström, B.; Sjöqvist, F.; Martenson, B.; Asberg, M. Slow hydroxylation of nortriptyline and concomitant poor de-brisoquine hydroxylation: clinical implications. Lancet, 1981, 339, 560-561.
3. Baumann, P.; Hiemke, C.; Ulrich, S.; Eckermann, G.; Gaertner, I.; Gerlach, M.; Kuss, H.J.; Laux, G.; Müller-Oelinghausen, B.; Rao, M.L.; Riederer, P.; Zernig, G. The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry, 2004, 37, 243-265.
4. Hiemke, C.; Baumann, P.; Bergemann, N.; Conca, A.; Dietmaier, O.; Egberts, K.; Fric, M.; Gerlach, M.; Greiner, C.; Gründer, G.; Haen, E.; Havemann-Reinecke, U.; Jaquenoud Sirot, E.; Kirchherr, H.; Laux, G.; Lutz, U.C.; Messer, T.; Müller, M.J.; Pfuhlmann, B.; Ram-beck, B.; Riederer, P.; Schoppek, B.; Stingl, J.; Uhr, M.; Ulrich, S.; Waschgler, R.; Zernig, G. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011 Pharmacopsy-chiatry, 2011, 44, 195-235.
5. Kirchheiner, J.; Brøsen, K.; Dahl, M.L.; Gram, L.F.; Kasper, S.; Roots, I.; Sjöqvist, F.; Spina, E.; Brockmöller, J. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr. Scand., 2001, 104(3), 173-192.
6. Kirchheiner, J.; Fuhr, U.; Brockmöller. Pharmacogenetics-based therapeutic recommendations--ready for clinical practice? J. Nat. Rev. Drug Discov., 2005, 4, 639-647.
7. Sapone, A.; Paolini, M.; Biagi, G.L.; Cantelli-Forti, G.; Gonzalez FJ. The pressing need for combined genotype-phenotype analysis in clinical practice. Trends Pharmacol. Sci. 2002, 23(6), 260-261.
8. de Leon, J.; Armstrong, S.C.; Cozza, K.L. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics, 2006, 47(1), 75-85.
9. Eichelbaum, M.; Ingelman-Sundberg, M.; Evans, W.E. Pharmaco-genomics and individualized drug therapy. Annu. Rev. Med., 2006, 57, 119-137.
10. Fuhr, U.; Jetter, A.; Kirchheiner, J. Appropriate phenotyping procedures for drugs metabolizing enzymes and transporters in humans and their simultaneaous use in the «cocktail» approach. Clin. Pharmacol. Ther., 2007, 81, 270-283.
11. Haen, E. Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety. Pharmacopsychiatry, 2011, 44, 254-258.
12. Lundmark, J.; Bengtsson, F.; Nordin, C.; Reis, M.; Walinder, J. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr. Scand., 2000, 101, 354-359.
13. Simmons, S.A.; Perry, P.J.; Rickert, E.D.; Browne, J.L. Cost-benefit analysis of prospective pharmacokinetic dosing of nortrip-tyline in depressed inpatients. J. Affect. Disord., 1985, 8, 47-53.
14. Vuille, F.; Amey, M.; Baumann, P. Use of plasma level monitoring of antidepressants in clinical practice - towards an analysis of clinical utility. Pharmacopsychiatry, 1991, 24, 190-195.
15. Shams, M.E.E.; Arneth, B.; Hiemke, C.; Dragicevic, A.; Müller, M.J.; Kaiser, R.; Lackner, K.; Härter, S. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J. Clin. Pharm. Ther., 2006, 31, 493-502.
16. Kootstra-Ros, J.E.; Van Weelden, M.J.; Hinrichs, J.W.; De Smet, P.A.; van der Weide, J. Therapeutic drug monitoring of antidepres-sants and cytochrome P450 genotyping in general practice. J. Clin. Pharmacol., 2006, 46(11),1320-1327.
17. Zanger, U.M.; Turpeinen, M.; Klein, K.; Schwab, M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem., 2008, 392(6), 1093-1108.
18. De Leon, J. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation. CNS Spectr., 2006, 11, 8-12.
19. Jaquenoud Sirot, E.; van der Velden, J.W.; Rentsch, K.; Eap, C.B.; Baumann, P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf., 2006, 29, 735-768.
20. Grözinger, M.; Dragicevic, A.; Hiemke, C.; Shams, M.; Müller, M.J.; Härtter, S. Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. Pharmacopsychiatry, 2003, 36, 3-6.
21. Turpault, S.; Brian, W.; Van Horn, R.; Santoni, A.; Poitiers, F.; Donazzolo, Y.; Boulenc, X. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br. J. Clin. Pharmacol., 2009, 68(6), 928-935.
22. Köhler, D.; Härtter, S.; Fuchs, K.; Sieghart, W.; Hiemke, C. CYP2D6 genotype and phenotyping by determination of dex-tromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics, 1997, 7(6), 453-461.
23. Lee, K.S.; Kim, S.K. Direct and metabolism-dependent cyto-chrome P450 inhibition assays for evaluating drug-drug interactions. J. Appl. Toxicol., 2011, 14. (http://onlinelibrary.wiley.com/doi/10.1002/jat.1720/pdf].
24. Zhang, W.; Han, F.; Guo, P.; Zhao, H.; Lin, Z.J.; Huang, M.Q.; Bertelsen, K.; Weng, N. Simultaneous determination of tolbu-tamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS--a high throughput approach to evaluate drug-drug interactions. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2010, 878, 1169-1177.
25. Zhu, B.; Ou-Yang, D.S.; Chen, X.P.; Huang, S.L.; Tan, Z.R.; He, N.; Zhou, H.H. Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin. Pharmacol. Ther., 2001, 70, 455-461.
26. Eap, C.B.; Jaquenoud Sirot, E.; Baumann, P. Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies. Ther. Drug Monit., 2004, 26, 152-155.
27. Martignoni, M.; Groothuis, G.M.; de Kanter, R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol., 2006, 2(6), 875-894.
28. Mann, K.; Hiemke, C.; Schmidt, L.G.; Bates, D.W. Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther. Drug Monit., 2006, 28, 83-88.
29. De Leon, J. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation. CNS Spectr., 2006, 11(3), 8-12.
30. Dantz, B. Clinical pharmacogenetics in psychiatry. Psychopharm. Rev., 2009, 44, 49-56.